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Chicken  anemia  virus  (CAV)  is  an  important  viral 
pathogen that causes anemia and severe immunodeficiency 
syndrome in chickens worldwide. In this study, a potential 
diagnostic  monoclonal  antibody  against  the  CAV  VP1 
protein was developed which can precisely recognize the 
CAV antigen for diagnostic and virus recovery purposes. 
The VP1 gene of CAV encoding the N-terminus-deleted VP1 
protein, VP1Nd129, was cloned into an Escherichia (E.) coli 
expression  vector.  After  isopropyl-β-D-thiogalactopy-
ronoside  induction,  VP1Nd129  protein  was  shown  to  be 
successfully  expressed  in  the  E.  coli.  By  performing  an 
enzyme-linked immunoabsorbent assay using two coating 
antigens, purified VP1Nd129 and CAV-infected liver tissue 
lysate, E3 monoclonal antibody (mAb) was found to have 
higher reactivity against VP1 protein than the other positive 
clones according to the result of limiting dilution method 
from 64 clones. Using immunohistochemistry, the presence 
of the VP1-specific mAb, E3, was confirmed using CAV- 
infected  liver  and  thymus  tissues  as  positive-infected 
samples. Additionally, CAV particle purification was also 
performed using an immunoaffinity column containing E3 
mAb. The monoclonal E3 mAb developed in this study will 
not only be very useful for detecting CAV infection and 
performing histopathology studies of infected chickens, but 
may also be used to purify CAV particles in the future.
Keywords: chicken anemia virus, immunoaffinity column, 
immunohistochemistry, monoclonal antibody, VP1
Introduction
Chicken anemia virus (CAV) is the sole member of the 
genus Gyrovirus of the Circoviridae family and causes 
severe anemia and chicken anemia disease, an immu-
nosuppressive disorder [3,13,14]. Histopathological 
studies have shown that CAV infection leads to aplasia of 
the bone marrow [10,21]. This results in anemia and severe 
immunodeficiency syndrome due to the destruction of T 
lymphoid tissue [10,21].
　The CAV genome consists of a circular single-stranded 
DNA genome of 2.3 kb encoding three viral proteins (VP): 
VP1, VP2 and VP3 [3,13,14]. VP1 is the sole structural 
protein of the CAV capsid. At a very late stage of the virus 
life cycle, the assembled virus particles created by VP1 
spread into various other tissues and organs of chickens 
such as the thymus, spleen, and liver. Among these tissues 
and organs, liver tissue has been reported to have the 
highest accumulation of CAV virions [21]. Several 
methods have been developed to conventionally detect 
CAV infection such as serological tests for identifying 
CAV antibodies. Recently, immunohistochemistry (IHC) 
and immunofluorescence (IF) have been used as alternative 
methods for detecting CAV antigen [1,11,12,17,18]. For 
these methods to be successful, an excellent monoclonal 
antibody is essential. Thus, antigen preparation is a critical 
factor when producing these monoclonal antibodies. It has 74    Yi-Yang Lien et al.
been reported that VP2 and VP3 have been used as target 
antigens to generate monoclonal antibodies for immunological 
characterization or for developing diagnostic enzyme-linked 
immunoabsorbent assay (ELISA) kits [5,21]. However, 
VP1 has rarely been used as the antigen for generating 
antibodies or for producing diagnostic kits. This is because 
problems with VP1 expression have been reported in 
several host cell systems [5,8,15,18].
　Research on VP1 antigen preparation has generally been 
unsuccessful because of a failure to find a good recombinant 
protein expression system. The highly enriched span of 
arginine residues at the N-terminus of VP1 has been 
proposed to be cytotoxic in an Escherichia  (E.) coli 
expression system [15]. Thus, there is a need to overcome 
the difficulties of VP1 antigen preparation. If successful, 
this would allow the generation of a monoclonal antibody 
against VP1 capsids that may potentially be used 
diagnostically for the clinical detection of CAV infections. 
Recently, our group has shown that the VP1Nd129 protein 
(amino acid residues 130∼450 of VP1), from which the 
first 129 amino acid residues of the VP1 N-terminus have 
been deleted, can be used to successfully express large 
amounts of the protein in prokaryotic cells [8].
　In this study, the truncated recombinant VP1Nd129 
protein was used as antigen in immune BALB/c mice to 
develop and produce a number of monoclonal antibodies 
for immunological applications. One of these monoclonal 
antibodies, E3, was selected for evaluating the ability of 
the monoclonal antibody to recognize VP1 in clinical 
samples infected with CAV including liver and thymus 
tissue. In addition, an immunoaffinity column containing 
E3 mAb as a ligand for virus particle purification also was 
investigated herein. The results of our study will be very 
useful for developing immunological tools to detect CAV, 
identifying CAV infection, or for performing CAV 
histopathology studies in chickens.
Materials and Methods
Virus strain and CAV-infected liver tissue
　CAV (CIA89) was provided by Professor Yi Yang Lein of 
the National Pingtung University of Science and 
Technology (Taiwan). Two 1 day old specific pathogen 
free (SPF) hybrid white leghorn chickens purchased from 
the Animal Health Research Institute of the Council of 
Agriculture (Taiwan) were used to propagate the virus by 
passaging 20% liver homogenates (0.1 mL per bird). The 
phosphate buffered saline was used to dilute the homogenates 
containing virus particles. These animals were inoculated 
orally with CIA-89 containing titers of 10
7.5TCID50. At 
10-days post-infection, the chicken sera were collected and 
used to confirm the virus infection in terms of the per-
formance of anti-CAV antibody using commercial CAV 
test kit (IDEXX, Netherlands). Then the chicken was 
sacrificed. The individual livers of the sacrificed chickens 
were removed, collected, immersed in formaldehyde, and 
then stored at room temperature until required. 
Plasmid construction and bacterial strain
　The pGEX-6P-1-VP1 plasmid derived from pGEX-6P-1 
plasmid (GE Healthcare, USA), which contains cDNA 
encoding the VP1 genes, was provided from Professor 
Yi-Yang Lien of National Pingtung University of 
Science and Technology (Taiwan) and initially used as 
the PCR template. To amplify the VP1 gene lacking the 
coding region for the first 129 amino acids from the 
full-length VP1 gene, two PCR primers, VP1-388FE and 
VP1-RHX, were designed and used as described in a 
previous study [8]. Using pGEX-6P-1-VP1 as the 
template, PCR reactions were performed at 95
oC for 5 
min, 95
oC for 45 sec, 59
oC for 50 sec, and 72
oC for 1 min 
for 30 cycles. The last PCR cycle was carried out with a 
final elongation step of 10 min at 72
oC. The amplified 
DNA fragments were digested with XhoI and EcoRI 
(Takara, Japan), and then cloned into the prokaryotic 
expression vector pET28a (Merck, Germany). The 
constructed recombinant plasmid, pET28a-VP1Nd129, 
was used to transform One Shot Top10 cells (Invitrogen, 
USA) and BL-21 (DE3) competent E. coli for maintaining 
the recombinant plasmids and for protein expression, 
respectively. Transformants with the correct gene size were 
identified by PCR and screened using restriction enzyme 
digestion and sequencing. The above PCR was performed 
in a 25 μL reaction mixture containing 0.4 mM of dNTPs, 
5 pmole each of VP1-388FE and VP1-RHX, 1U Pro-taq 
DNA polymerase (Protech, Taiwan) and 1× Pro-taq buffer 
(10 mM Tri-HCl, 50 mM KCl, 0.01% gelatin, 1.5 mM 
MgCl2, 0.1% Triton X-100, pH 9.0). The PCR conditions 
was 95
oC for 5 min, followed by 35 cycles of 95
oC for 1 
min, 57.7
oC for 1 min, and 72
oC for 1 min, and a final 
extension cycle at 72
oC for 10 min. Digestion was carried 
out at 37
oC for 1 h in a 50 μL reaction mixture containing 
50 mM of potassium acetate, 20 mM Tris-acetate, 10 
mM magnesium acetate, 1 mM DTT, 100 μg/mL BSA, 
5U XhoI and 5U EcoRI. The resulting restriction digestion 
product was analyzed by 1% agarose electrophoresis and 
visualized using ethidium bromide staining and UV. 
Expression and purification of VP1Nd129 protein 
in recombinant E. coli 
　Recombinant BL-21 (DE3) E. coli containing pET28a- 
VP1Nd129 were used for protein induction and expression. 
The recombinant strains were grown overnight in Luria- 
Bertani (LB) medium (BD-Difco, USA) in the presence of 
kanamycin (50 μg/mL; Amresco, USA) at 37
oC. Next, 0.5 
mL of the overnight culture was used to inoculate 50 mL 
LB medium. The culture was grown at 37
oC for around 3 
h by which time the optical density had reached 0.5. At Development and characterization of a diagnostic monoclonal antibody against CAV VP1 capsid    75
this point, 0.1 mM isopropyl-β-D-thiogalactopyronoside 
(IPTG) (Amresco, USA) was added to the culture to induce 
protein expression, which continued for 6 h. The presence 
of expressed VP1Nd129 protein was confirmed by 12.5% 
SDS-PAGE followed by Western blotting using a 
monoclonal anti-His antibody (Invitrogen, USA), as 
described in previously work [8]. 
　To purify the recombinant VP1Nd129 protein, a cell 
pellet was spun down using 5,000 × g, 15 min, at 4
oC from 
50 mL of the culture supernatant and resuspended in 
denaturing binding buffer (20 mM NaH2PO4, 0.5 M NaCl, 
and 8 M urea, pH 7.8). The mixture was then sonicated on 
ice three times for 3 min with a 20% pulsed activity cycle 
(Sonics & Materials, USA), and then centrifuged for 10 
min at 13,300 × g to remove cell debris. The resulting cell 
lysate was poured into an Enco-column (Bio-Rad, USA) 
with 2 mL of Ni
2+-NTA agarose and the resin was allowed 
to settle by gravity. The packed resin in column was 
washed by gravity with three volumes of denaturing 
binding buffer and then a similar volume of wash buffer 
(20 mM NaH2PO4, 0.5 M NaCl, and 8 M urea, pH 6.3). 
Finally, the bound proteins were eluted with elution buffer 
(20 mM NaH2PO4, 0.5 M NaCl, and 8 M urea, pH 4). For 
each fraction, 2 mL of elute was collected. The fractions 
were monitored at OD280 using a U-2001 spectropho-
tometer (Hitachi, Japan) with wash buffer as a blank. 
Putative peaks corresponding to the recombinant CAV 
viral protein were identified and the eluate was collected 
for analysis. The total protein concentration of each 
fraction was determined using a Micro BCA kit (Pierce, 
USA) with bovine serum albumin as the reference protein. 
The purity of the protein samples was analyzed using 
aliquots of the concentrated fraction; this was done by 
12.5% SDS-PAGE and Coomassie brilliant blue staining.
Generation of a monoclonal antibody against CAV 
VP1 protein
　SPF BALB/c mice (Charles River, MA) were immunized 
by subcutaneous injection of 20 μg purified VP1Nd129 
protein emulsified with complete Freund’s adjuvant 
(Sigma-Aldrich, USA). After immunization, the BALB/c 
mice were sacrificed, the spleens were removed, and the 2 
× 10
8 splenocytes were fused with 2 × 10
7 SP2/0 myeloma 
cells (ATCC CRL1581) by treatment with polyethylene 
glycol [6]. After 2 weeks of growth, the resultant 
hybridomas were examined the presence of antibodies 
against VP1Nd129 protein. Antibodies secreted from the 
various hybridomas were screened by ELISA. They were 
subcloned three times using the limiting dilution technique 
[20], and then ascitic fluid containing monoclonal 
antibodies was produced by introducing the cloned 
hybridomas into Pristane-primed mice (Charles River, 
USA). The immunoglobulin class of the hybridoma 
antibodies was determined by ELISA with a Mab kit 
(Zymed Laboratories, USA) using rabbit antisera against 
mouse immunoglobulin (Ig)M, IgG1, IgG2a, IgG3, and 
IgA, and goat anti-rabbit IgG serum conjugated with 
horseradish peroxidase (HRP).
ELISA
To evaluate the specificity and reactivity of the mAb 
against CAV, an ELISA with the antibody was performed 
with purified VP1Nd129 protein or lysates from tissues 
infected with CAV as the antigen. After this, polyvinyl 
chloride 96-well plates were coated with recombinant 
VP1Nd129 or tissue lysates containing CAV. The antigen 
was buffered and diluted with carbonate-bicarbonate 
buffer (pH 9.6). Varying amounts of antigen from 1 to 500 
ng were added to the 96-well strip plate and incubating 
overnight at 4
oC. After antigen coating, the plates were 
washed twice with phosphate-buffered saline (PBS), 
containing 0.05% Tween 20 (PBS-T), and then 0.2 mL of 
blocking reagent (PBS containing 5% skim milk) was 
added to each well. After 30 min of incubation at room 
temperature, the plates were washed twice with PBS. One 
hundred  μL of the hybridoma supernatants were then 
added to the plate wells coated with CAV antigen or 
recombinant antigen and incubated at 37
oC for 1 h. The 
bound mAbs were detected using HRP-conjugated rabbit 
anti-mouse IgG (Jackson Immuno Research, USA) and 
the color was developed with o-phenylenediamine 
dihydrochloride (Sigma-Aldrich, USA). 
Histopathology and IHC
   CAV-infected and uninfected liver and thymus tissues 
(positive and negative controls, respectively) were all from 
clinical cases of CAV infection confirmed by PCR using 
specific primers as previously described [8]. The liver and 
thymus samples were fixed using 30% neutral buffered 
formaldehyde and embedded in paraffin. The paraffin- 
embedded tissues were sectioned, mounted, and then 
stained with hematoxylin and eosin. IHC staining was 
carried out at room temperature. Tissue sections (5-μm 
thick) of the paraffin-embedded tissues were washed with 
phosphate saline buffer containing 0.3% hydrogen peroxide 
to inactivate endogenous peroxidase. After washing three 
times with phosphate saline buffer, antigen retrieval was 
carried out by incubating the tissue sections with a 0.1% of 
phosphate buffer diluted trypsin solution. The 250 fold 
diluted monoclonal antibody E3 mAb, which is specific for 
CAV VP1, was then applied as the primary antibody for 2 
hours of the incubation. E3 mAb was recognized by 
HRP-conjugated goat anti-mouse IgG secondary antibody 
(Jackson ImmunoResearch, USA). 0.2 μg/mL of secondary 
antibody solution was used for 2 h of the incubation. After 
IHC staining, the sections were counterstained with 
hematoxylin and examined under light microscopy.76    Yi-Yang Lien et al.
Fig. 1. Analysis of the VP1Nd129 protein expressed in 
recombinant  Escherichia  (E.) c o l i  by SDS-PAGE (A) and 
Western blotting (B). The symbols ‘򰠏’ and ‘+’ represent pre- and 
post-induction with 1 mM of isopropyl-β-D-thiogalactopyronoside
in E. coli, respectively. Anti-His tag monoclonal antibody was used
for recognizing the VP1Nd129 protein. The arrowheads are the 
symbol for expressed VP1Nd129 protein.
Immunofluorescence 
For IF microscopy, infected and un-infected MSB-1 cells 
on glass coverslips were fixed in 4% formaldehyde, washed 
with PBS, and permeabilized with 0.01% Triton X-100. 
After washing with PBS, samples were incubated with 
blocking solution (0.5% bovine serum albumin in PBS) for 
1 h, followed by 1 h of incubation with 2 μg/mL of E3 
mAb solution. 0.2 μg/mL of fluorescein isothiocyanate- 
conjugated goat anti-mouse IgG (Jackson Immuno-
Research, USA) was used to detect E3 mAb binding. Cell 
nuclei were counterstained with 4´,6-diamidino-2- 
phenylindole (Sigma-Aldrich, USA) and fluorescence 
images were captured using a laser scanning confocal 
microscope (Leica Microsystems, Germany).
Immunoaffinity column purification of CAV particles
To create an immunoaffinity column, cytoplasmic 
extracts from chicken liver tissues infected with CAV were 
prepared by centrifugation at 13,300 × g for 30 min at 44
oC. 
Next, 100 μL of cell extract were mixed with 50 μL of 
ascitic fluid and incubated overnight at 4°C. Then, 50 μL of 
protein A agarose beads (Sigma-Aldrich, USA) were 
added and incubated overnight at 44
oC with gentle 
rotation. The agarose beads were washed three times with 
buffer containing 50 mM Tris-HCl (pH 7.5), 500 mM 
NaCl, 0.2% NP-40, and 0.05% sodium deoxycholate. 
Finally, viral protein and/or CAV virus particles were 
eluted from the protein A agarose beads by boiling with 
SDS-PAGE sample buffer (60 mM Tris-Cl pH 6.8, 2% 
SDS, 10% glycerol, 5% β-mercaptoethanol, 0.01% 
bromophenol blue) for 5 min. The extracted proteins were 
then subjected to SDS-PAGE followed by Western blotting 
using E3 mAb as primary antibody and HRP-conjugated 
goat anti-mouse IgG secondary antibody, respectively. In 
addition, CAV genomic DNA from the CAV virus particles 
was detected by PCR using CAV genome-specific primers. 
The sequences of the CAV VP1 gene PCR primers were 
VP1F: 5´-ATGGCAAGACGAGCTCGCAGACCGAGA 
GG-3´ and VP1R: 5´-CTAACCATGGTGATGGTGATG 
GTGGGGCTGCGTCCCCCAGTA-3´. The sequences of 
the CAV VP3 primers were VP3F: 5´-CCGCTCGAGC 
AGTCTTATACACCTTCTTG-3´ and VP3R: 5´-GCGAA 
TTCATGAACGCTCTCCAAGAAGATAC-3´. The PCR 
conditions was 95
oC for 5 min, followed by 35 cycles of 
95
oC for 1 min, 57.7
oC for 1 min, and 72
oC for 1 min, and 
a final extension cycle at 72
oC for 10 min.
Results 
Expression,  purification  and  characterization  of 
CAV  VP1Nd129  protein  using  a  recombinant  E. 
coli system
   To express the CAV VP1 as an antigen for immunization, 
the VP1Nd129 construct was created by PCR using VP1 
cDNA as the template DNA. The VP1 cDNA partially 
overlapped partially the VP2 gene of the CAV genome, 
which had been previously cloned into the pGEX-6P-1 
plasmid [4]. Using the primers VP1-388FE and 
VP1-RHX, the VP1Nd129 construct was amplified by 
PCR and cloned into the pET28 a vector at the EcoRI and 
XhoI sites, thereby creating a protein with an in-frame 
His-tag. This plasmid, pET28a-VP1Nd129, was used to 
transform E. coli BL-21 (DE3) cells. The E. coli were 
examined for protein expression after 4 h of induction with 
IPTG. VP1Nd129 protein was successfully expressed in E. 
coli, as noted by the correct size band on a gel stained with 
Coomassie blue gel and recognition by anti-His tag 
antibodies (Fig. 1). The estimated molecular weight of 
pET28a-VP1Nd129 was 40 kDa. VP1Nd129 in E. coli was 
expressed at a high level which reached 26.2 mg/L when 
0.1 mM IPTG was added to the culture broth. After affinity 
chromatography purification, the purified VP1Nd129 
protein was confirmed by Western blotting using anti-His 
and anti-CAV antibodies. The purity of VP1Nd129 
approached homogenicity in elution fractions E1 to E7 at 
pH 4.0. Purification of His-tag-fused VP1Nd129 was 
therefore feasible using a Ni-NTA column. Additionally, 
the identity of the Ni-NTA-purified VP1Nd129 protein 
was confirmed by mass spectrometry (data not shown).
Screening and characterization of mAbs specific for 
VP1 
To establish monoclonal antibodies, spleen cell were Development and characterization of a diagnostic monoclonal antibody against CAV VP1 capsid    77
Fig. 2. Analysis of the specificity and reactivity of E3 monoclonal
antibody (mAb) by Western blotting (A) and ELISA (B). 
Different amounts of purified VP1Nd129 or E. coli cell lysate 
were reacted with E3 mAb in both (A) and (B).
Fig. 3. Immunohistochemical labeling of chicken anemia virus 
(CAV)-infected chicken liver tissues. E3 mAb was used as the 
primary antibody for recognizing CAV antigen in liver tissue. 
(A) Negative control. (B) CAV-infected chicken liver tissue. 
Scale bars = 100 nm.
Fig. 4. Immunohistochemical labeling of CAV-infected chicken
thymus tissues. E3 mAb was used as the primary antibody for 
recognizing CAV antigen in the thymus tissue. (A) Negative 
control. (B) CAV-infected chicken thymus tissue. Scale bars = 
100 nm.
removed from five mice immunized with Ni-NTA-purified 
recombinant VP1Nd129 protein and fused with SP2/0 
myeloma cells. After 14 days, hybridoma cell lines 
secreting mAbs specific for VP1Nd129 were screened by 
ELISA using the Ni-NTA-purified VP1Nd129 protein as 
the coating antigen. Four mAbs were found active against 
VP1Nd129 (B1-1, B1-5, D4 and E3) were identified out of 
64 clones; these were then screened by subcloning at least 
three times using the limiting dilution method. The mAb 
from the E3 hybridoma cells showed the greatest reactivity 
compared to the other mAbs from the B1-1, B1-5, and D4 
hybridomas (data not shown). Even after the supernatant 
was diluted 50-fold, E3 still has recognition activity to 
react the antigen. In addition, the specificity and reactivity 
of the E3 mAb were also confirmed by Western blotting 
using purified recombinant VP1Nd129 and E. coli cell 
lysates. As illustrated in Fig. 2A, the E3 mAb showed good 
specificity and reactivity against the antigen and purified 
recombinant VP1Nd129 while showing no reaction against 
cell lysates from E. coli harboring the blank pET28a vector.
  When the specificity of the E3 mAb against different 
amounts of antigens was evaluated, it was found to be 
constant and the reactivity of the E3 mAb increased with 
increasing amounts of antigen. There were very few 
background bands that reacted with E3 mAb in either the 
samples of purified VP1Nd129 or the E. coli cell lysate. 
Moreover, 1 ng of purified VP1Nd129 was sufficient to 
react with E3 mAb (Fig. 2B). Thus, E3 mAb has good 
specificity and reactivity against CAV antigen. Additionally, 
IgG subtype analysis showed that E3 mAb was IgG2b 
with a κ light chain. At this point, the E3 hydridoma was 
selected to produce mAbs in mice. Mouse ascitic fluid was 
then used for further diagnostic applications and cha-
racterization.
Diagnostic  application  of  the  E3  MAb  for  CAV 
detection 
To evaluate the possible clinical application of E3 mAb 
for CAV diagnosis, the mAb was used for CAV detection 
by IHC and immunochromatographic assay. First, four 
CAV-infected chicken livers were analyzed using IHC; all 
of the paraffin-embedded tissues were positive. The positive 
control slides demonstrated strong immunoreactivity 
against CAV antigen (Fig. 3B). In addition, four CAV 
mock-infected chicken livers were analyzed as the negative 
control; these were all negative for immunoreactivity 
against CAV antigen, (Fig. 3A). Moreover, similar im-
munoreactivity results were found in the thymus tissues. 
The CAV-infected thymus shown in Fig. 4B was 
recognized by the E3 mAb using IHC in contrast to the 
negative sample (Fig. 4A). 
  In CAV-infected MSB-1 cells and CAV-infected MSB-1 
showing a CPE, the presence of VP1 antigen in the cells 
was recognized by the E3 mAb using an IF assay (Fig. 5). 
These results indicated that E3 mAb was able to 
discriminate CAV-infected tissues or cells from uninfected 
tissue or cells in experimental samples using IHC staining 
and IF, respectively. Furthermore, E3 mAb was used to 
react with VP1 present in the lysate of CAV-infected liver 
tissue. As illustrated in Fig. 6A, VP1 with a molecular 
weight of 50 kDa was eluted from the protein A agarose 
beads. In contrast, no VP1 was detected from the eluted 78    Yi-Yang Lien et al.
Fig. 5. Immunofluorescence assay of CAV-infected chicken 
MSB-1 cells. E3 mAb was used as the primary antibody for 
recognizing CAV VP1 antigen in the MSB-1 cells. The 
fluorescent agent 4´,6-diamidino-2-phenylindole (DAPI) and 
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse 
immunoglobulin G (IgG) were used to counterstain the cell 
nuclei of cultures and react with E3 mAb, respectively. CPE: 
CAV-infected MSB-1 cells showing a cytopathic effect.
Fig. 6. Western blotting of immunocolumn-purified CAV VP1 by
E3 mAb (A). CAV-infected liver lysate reacted with E3 mAb and
immunoaffinity resin was then used to precipitate the 
mAb-bound or unbounded antigen. Lane M: pre-stained protein
marker (the molecular weights of respective bands are 116, 66, 
45, 35, 25, and 18 kDa), Lane 1: uninfected liver lysate, Lane 2: 
CAV-infected liver lysate, Lane 3: VP1 protein co-precipitated 
with E3 mAb from tissue lysate of Lane 2, Lane 4: E3 mAb only,
Lane 5: protein precipitated by E3 mab from tissue lysate of Lane
1. “H” and “L” indicate the IgG heavy and light chains, respectively.
Identification of the CAV genome by PCR (B). CAV VP1 capsid 
was co-precipitated with E3 mAb and then used to as a DNA 
template for PCR amplification using primers specific for the 
VP1 and VP2 genes. Lane M: 1-kb DNA ladder marker, Lane 1:
positive PCR control, Lane 2: uninfected liver lysate, Lane 3: 
CAV-infected liver lysate, Lane 4: sample co-precipitated with 
E3 mAb from CAV-infected liver lysate. sample of CAV mock-infected liver lysate. Detection of the 
protein was performed by Western blotting using E3 mAb 
as the primary antibody. In addition, Fig. 6B shows that 
CAV-specific VP1 and VP3 genes with lengths of 1.35 kb 
and 348 bp, respectively, were amplified by PCR using the 
eluted fraction from the immunochromatographic column 
as a template. This suggests that the eluted fraction from 
the immunochromatographic column included the CAV 
VP1 capsid.
Discussion
In this study, we successfully generated a specific 
monoclonal antibody, E3 mAb, which is active against VP1, 
the sole structural protein of CAV. To generate monoclonal 
or polyclonal antibodies against VP1, purified CAV particles 
are usually used as the main antigen for producing the 
antibodies. However, virion purification is very tedious and 
time-consuming. Therefore, DNA recombinant technology 
was chosen as a better method for producing VP1.
Previously, several expression systems have been used to 
express CAV VP1, including E. coli, baculovirus-insect 
cells, and plant cells [5,6,15]. However, expressing full- 
length VP1 protein has been difficult because of cytotoxicity 
[15]. Moreover, production of the recombinant full-length 
VP1 protein has generally been unsuccessful because of a 
failure to express a span of amino acids at the N-terminus 
that is highly rich in arginine residues [8,15]. This might 
because these amino acids are encoded by codons that are 
rarely used by E. coli. Most viral capsid proteins of 
circoviruses such as porcine circovirus and pigeon 
circovirus including the rare codons of E. coli at N-terminus 
have been investigated in previous studies. Truncation of 
the N-terminus of capsid proteins has therefore become an 
alternative way to produce these recombinant viral proteins 
[2,9]. Thus, as can be resolved using above truncated 
recombinant protein, monoclonal antibodies or detection 
kit could be generated [2,4,5,9,13]. Lee et al. [8] reported 
that the expression of VP1 in a host system can be vastly 
improved when the arginine residues at the VP1 
N-terminus are removed. Using this N-terminus- truncated 
clone of VP1 expressed in E. coli, we successfully produced 
and purified VP1Nd129 protein. After using this antigen to 
create E3 mAb against VP1, this antibody was evaluated 
in terms of its use in IHC, IF, and immunoaffinity 
chromatographic column purification. Several diagnostic 
methods have been developed and refined for detecting 
CAV infection including electron microscopy, nucleic 
acid-based analysis, and antigen-antibody assays [11,12,17,18]. 
IF assays have been most commonly used for diagnosing 
CAV infections. Combining IF and confocal laser scanning 
microscopy would establish a highly convenient method 
for directly investigating CAV biology at a subcellular 
level. 
  It is well known that VP1 is the sole structural protein of 
CAV; thus this protein is a highly useful marker for 
detecting CAV. In the life cycle of CAV, VP1 encapsidates 
the CAV genome during virus particle assembly [16]. The 
fact that VP1 capsid was eluted from the protein A agarose 
beads in this study implies that the CAV genome co-eluted 
with the VP1 protein. When CAV virions purified by 
immunoaffinity column were analyzed by PCR, CAV-specific Development and characterization of a diagnostic monoclonal antibody against CAV VP1 capsid    79
gene amplification was observed, which confirmed the 
presence of assembled virus particles.
Epitope mapping of VP1 in terms of mAb recognition 
was not performed in this study. However, mAb E3 might 
recognize a specific epitope that is located on the surface of 
VP1 particles. Thus, it is possible that E3 mAb might 
recognize a neutralizing epitope and the antibody could as 
a virus neutralizing antibody. This could be determined in 
the future by means of a virus neutralization assay and 
would help with the development of a peptide vaccine for 
controlling CAV infections. 
In conclusion, we generated monoclonal antibodies 
against recombinant VP1Nd129 protein using a mouse 
hybridoma system. The most immunodominant epitope, 
VP1 of the CAV capsid, was detected immunologically 
using one of these monoclonal antibodies, E3 mAb. This 
monoclonal antibody enabled the visualization of the viral 
antigen in formalin-fixed tissue samples by IHC. In the 
absence of virus recovery, diagnosing CAV infection could 
be achieved by an immunological approach using E3 mAb 
for antigen detection. Therefore, the immunological probe 
generated in this study represents a powerful tool that will 
promote the development of CAV diagnostic systems for 
epidemiological investigations. In addition, these systems 
will assist with measuring the immunization efficacy of 
vaccines, enhance the study of CAV biology, and enable 
general surveillance of CAV infections.
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